159 related articles for article (PubMed ID: 241143)
1. Bone marrow transplantation in the busulfan-treated rat. I. Effect of cyclophosphamide and rabbit antirat thymocyte serum as immunosuppression.
Tutschka PJ; Santos GW
Transplantation; 1975 Aug; 20(2):101-6. PubMed ID: 241143
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow transplantation in the busulfan-treated rat. II. Effect of cyclophosphamide and antithymic serum on the presensitized state.
Tutschka PJ; Santos GW
Transplantation; 1975 Aug; 20(2):116-22. PubMed ID: 809876
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow transplantation in the busulfin-treated rat. III. Relationship between myelosuppression and immunosuppression for conditioning bone marrow recipients.
Tutschka PJ; Santon GW
Transplantation; 1977 Jul; 24(1):52-62. PubMed ID: 18820
[No Abstract] [Full Text] [Related]
4. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
[TBL] [Abstract][Full Text] [Related]
5. The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases.
Rosales F; Peylan-Ramu N; Cividalli G; Varadi G; Or R; Naparstek E; Slavin S; Nagler A
Bone Marrow Transplant; 1999 May; 23(9):861-5. PubMed ID: 10338039
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of transient treatment with FK506 in the early phase on cyclophosphamide-induced bone marrow chimerism and transplant tolerance across MHC barriers.
Okayama J; Ko S; Kanehiro H; Kanokogi H; Nakajima Y
J Surg Res; 2006 Jun; 133(2):61-8. PubMed ID: 16376943
[TBL] [Abstract][Full Text] [Related]
7. Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage.
He X; Ye Y; Xu X; Wang J; Huang Y; Weng G; Zhang M; Guo K
Biomed Res Int; 2016; 2016():3071214. PubMed ID: 27843940
[TBL] [Abstract][Full Text] [Related]
8. Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice.
Nilsson C; Forsman J; Hassan Z; Abedi-Valugerdi M; O'Connor C; Concha H; Jansson M; Hassan M
Exp Hematol; 2005 Mar; 33(3):380-7. PubMed ID: 15730862
[TBL] [Abstract][Full Text] [Related]
9. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
[TBL] [Abstract][Full Text] [Related]
10. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation.
Uharek L; Gassmann W; Glass B; Steinmann J; Loeffler H; Mueller-Ruchholtz W
Blood; 1992 Mar; 79(6):1612-21. PubMed ID: 1547350
[TBL] [Abstract][Full Text] [Related]
11. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
Prigozhina TB; Elkin G; Khitrin S; Slavin S
Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary complications of bone marrow transplantation: a comparison of total body irradiation and cyclophosphamide to busulfan and cyclophosphamide.
Hartsell WF; Czyzewski EA; Ghalie R; Kaizer H
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):69-73. PubMed ID: 7536723
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma.
Bensinger WI; Buckner CD; Clift RA; Petersen FB; Bianco JA; Singer JW; Appelbaum FR; Dalton W; Beatty P; Fefer A
J Clin Oncol; 1992 Sep; 10(9):1492-7. PubMed ID: 1517792
[TBL] [Abstract][Full Text] [Related]
14. The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment.
Glass B; Uharek L; Gaska T; Gassmann W; Löffler H; Müller-Ruchholtz W
Bone Marrow Transplant; 1993; 12 Suppl 3():S41-7. PubMed ID: 8124257
[TBL] [Abstract][Full Text] [Related]
15. Effect of antithymocyte globulin pretreatment on immunological reconstitution of lethally irradiated animals.
Allen EM; Gengozian N
Transplantation; 1975 Jun; 19(6):456-63. PubMed ID: 237349
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA
Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
[TBL] [Abstract][Full Text] [Related]
17. Prevention of graft-versus-host disease and the induction of transplant tolerance by low-dose UV-B irradiation of BM cells combined with cyclosporine immunosuppression.
Ohajekwe OA; Hardy MA; Oluwole SF
Transplantation; 1995 Dec; 60(12):1510-6. PubMed ID: 8545883
[TBL] [Abstract][Full Text] [Related]
18. Use of cyclosporin A (CsA) in a rat model of allogeneic marrow transplantation.
Tutschka PJ; Beschorner WE; Hess AD
Haematol Blood Transfus; 1980; 25():241-53. PubMed ID: 7021342
[No Abstract] [Full Text] [Related]
19. Bone marrow transplantation across major histocompatibility barriers in mice. II. T cell requirement for engraftment in total lymphoid irradiation-conditioned recipients.
Vallera DA; Soderling CC; Carlson GJ; Kersey JH
Transplantation; 1982 Mar; 33(3):243-8. PubMed ID: 6121405
[TBL] [Abstract][Full Text] [Related]
20. Prevention of graft-versus-host disease in rat small bowel transplantation by recipient pretreatment with UV-B-modulated bone marrow cells.
Chowdhury NC; Jin MX; Oluwole SF
Transplantation; 1993 Jun; 55(6):1229-35. PubMed ID: 8516807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
